Range of qualified sufferers: CDEC discussed the uncertainty in the amount of people with moderately severe to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some sufferers who're classified as having moderate or reasonable condition might have a extreme bleeding phenotype, which https://clarencee790yyy1.bloggosite.com/profile